Clinical trial

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

NCT03006887

Study summary

ClinicalTrials.gov

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record lenvatinib Normalized identity: lenvatinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record pembrolizumab Normalized identity: pembrolizumab View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-01-12

PhasePHASE1

Conditions

Solid Tumorsunresolved

Interventions

lenvatinibDRUG · verified · RxNorm: lenvatinib

pembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Eisai Co., Ltd.lead sponsor

Merck Sharp & Dohme LLCcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03006887 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.